{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T09:05:41Z","timestamp":1777626341897,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010408","name":"Polpharma Scientific Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010408","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.ahj.2019.06.009","type":"journal-article","created":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T23:26:47Z","timestamp":1560900407000},"page":"78-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Long-term follow-up and safety assessment of angiogenic gene therapy trial VIF-CAD: Transcatheter intramyocardial administration of a bicistronic plasmid expressing VEGF-A165\/bFGF cDNA for the treatment of refractory coronary artery disease"],"prefix":"10.1016","volume":"215","author":[{"given":"Krzysztof","family":"Kuku\u0142a","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arkadiusz","family":"Urbanowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariusz","family":"K\u0142opotowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"D\u0105browski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Pr\u0119gowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"K\u0105dziela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zbigniew","family":"Chmielak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Witkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Witold","family":"Ru\u017cy\u0142\u0142o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2019.06.009_bb0005","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/euhj.2001.2706","article-title":"The problem of chronic refractory angina: report from the ESC Joint Study Group on the Treatment of Refractory Angina","volume":"23","author":"Mannheimer","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2019.06.009_bb0010","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1093\/eurheartj\/eht165","article-title":"Long-term survival in patients with refractory angina","volume":"34","author":"Henry","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2019.06.009_bb0015","doi-asserted-by":"crossref","unstructured":"Povsic TJ, Broderick S, Anstrom KJ, Shaw LK, Ohman EM, Eisenstein EL, Smith PK, Alexander JHPredictors of long-term clinical endpoints in patients with refractory angina. J Am Heart Assoc 2015;4 pii: e001287.","DOI":"10.1161\/JAHA.114.001287"},{"key":"10.1016\/j.ahj.2019.06.009_bb0020","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0735-1097(03)00988-4","article-title":"A randomized, double-blind, placebo-controlled trial of Ad 5 FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina","volume":"42","author":"Grines","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.06.009_bb0025","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1161\/01.CIR.0000070540.80780.92","volume":"107","author":"Hedman","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2019.06.009_bb0030","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jacc.2004.12.068","article-title":"Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina A randomized double-blind placebo-controlled study: the Euroinject","volume":"45","author":"Kastrup","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.06.009_bb0035","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1089\/hum.2013.2516","article-title":"Gene therapy to stimulate angiogenesis to treat diffuse coronary artery disease","volume":"24","author":"Kaminsky","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ahj.2019.06.009_bb0040","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1093\/eurheartj\/ehx352","article-title":"Adenoviral intramyocardial VEGF-D\u0394N\u0394C gene transfer increases myocardial perfusion reserve in refractory angina patients: a phase I\/IIa study with 1-year follow-up","volume":"38","author":"Hartikainen","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2019.06.009_bb0045","first-page":"1365","article-title":"Angiogenic gene therapy in cardiovascular diseases: dream or vision?","volume":"38","author":"Yl\u00e4-Herttuala","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2019.06.009_bb0050","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1089\/hum.2012.137","article-title":"Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease","volume":"24","author":"Rosengart","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ahj.2019.06.009_bb0055","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ahj.2010.11.023","article-title":"Intramyocardial plasmid encoding human vascular endothelial growth factor A165\/basic fibroblast growth factor therapy using percutaneous transcatheter approach in patients with refractory coronary artery disease (VIF-CAD)","volume":"161","author":"Kuku\u0142a","year":"2011","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.ahj.2019.06.009_bb0060","first-page":"116","volume":"2","author":"Kuku\u0142a","year":"2006","journal-title":"Post Kardiol Int"},{"key":"10.1016\/j.ahj.2019.06.009_bb0065","article-title":"Approaches to therapeutic angiogenesis for ischemic heart disease","author":"Johnson","year":"2018","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.ahj.2019.06.009_bb0070","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/gt.2009.4","article-title":"Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer","volume":"16","author":"Hedman","year":"2009","journal-title":"Gene Ther"},{"key":"10.1016\/j.ahj.2019.06.009_bb0075","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1089\/hum.2012.137","article-title":"Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease","volume":"24","author":"Rosengart","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ahj.2019.06.009_bb0080","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/gt.2011.109","article-title":"10-year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb","volume":"19","author":"Muona","year":"2012","journal-title":"Gene Ther"},{"key":"10.1016\/j.ahj.2019.06.009_bb0085","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/gt.2011.85","article-title":"Long-term safety of intramuscular gene transfer of non-viral FGF1 for peripheral artery disease","volume":"19","author":"Niebuhr","year":"2012","journal-title":"Gene Ther"},{"key":"10.1016\/j.ahj.2019.06.009_bb0090","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1161\/ATVBAHA.111.244632","article-title":"Long-term follow-up evaluation of results from clinical trial using hepatocyte growth factor gene to treat severe peripheral arterial disease","volume":"32","author":"Makino","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2019.06.009_bb0095","first-page":"899","article-title":"High-dose plasmid-mediated VEGF gene transfer is safe in patients with severe ischemic heart disease (Genesis-I). A phase I, open-label, two-year follow-up trial","volume":"82","author":"Favaloro","year":"2013","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2019.06.009_bb0100","first-page":"1215","article-title":"Revascularization in \"no option\" patients with refractory angina: Frequency, etiology and outcomes","volume":"92","author":"Sharma","year":"2018","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2019.06.009_bb0105","doi-asserted-by":"crossref","DOI":"10.1111\/1755-5922.12461","article-title":"Vascular endothelial growth factor gene transfer therapy for coronary artery disease: A systematic review and meta-analysis","volume":"36","author":"Yuan","year":"2018","journal-title":"Cardiovasc Ther"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319301541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319301541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:02:36Z","timestamp":1757570556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870319301541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":21,"alternative-id":["S0002870319301541"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2019.06.009","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term follow-up and safety assessment of angiogenic gene therapy trial VIF-CAD: Transcatheter intramyocardial administration of a bicistronic plasmid expressing VEGF-A165\/bFGF cDNA for the treatment of refractory coronary artery disease","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2019.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}